Valuation: Insmed Incorporated

Market Cap 23.87B 20.86B 19.28B 17.81B 33.55B 2,292B 34.15B 230B 90.21B 1,123B 89.65B 87.67B 3,865B P/E 2026 *
-42.5x
P/E 2027 * 190x
Enterprise Value 23.3B 20.36B 18.82B 17.39B 32.75B 2,238B 33.34B 224B 88.08B 1,096B 87.52B 85.59B 3,774B EV / Sales 2026 *
13.8x
EV / Sales 2027 * 8.32x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -
1 day-0.12%
1 week-6.37%
Current month+2.34%
1 month+11.95%
3 months-25.64%
6 months-31.49%
Current year-37.31%
1 week 107.33
Extreme 107.33
119.54
1 month 93.92
Extreme 93.92
119.54
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 20.16
Extreme 20.164
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
07-08Fiscal year

Chief Executive Officer

32,097 0.0148%
07-05Fiscal year

Chief Technology Officer

36,906 0.0170%
06-24Fiscal year

Chief Executive Officer

64,194 0.0296%
Change 5-day change 1-year change 3-year change Capi.($)
-0.18%-6.37%+6.07%+427.10% 23.87B
-0.71%-5.45%+57.21%+72.81% 54.49B
+6.05%+7.79%+62.23%+88.46% 55.93B
-0.15%-3.85%-18.73%-16.12% 22.86B
+3.51%+10.88%+44.84%-3.21% 20B
+2.04%-0.24%+38.68%-29.73% 17.48B
-4.00%-10.96%+181.91%+328.17% 15.39B
+7.69%+11.91%+50.03%+720.96% 15.19B
-0.61%-2.48%+24.19%+185.15% 14.02B
+0.40%-5.88%+71.04%+138.61% 12.38B
Average +1.41%-0.33%+51.75%+191.22% 25.16B
Weighted average by Cap. +1.80%+0.38%+50.34%+152.90%

Financials

2026 *2027 *
Net sales 1.69B 1.48B 1.36B 1.26B 2.37B 162B 2.42B 16.27B 6.38B 79.45B 6.34B 6.2B 274B 2.75B 2.4B 2.22B 2.05B 3.87B 264B 3.94B 26.51B 10.4B 129B 10.34B 10.11B 446B
Net income -567M -495M -458M -423M -797M -54.44B -811M -5.46B -2.14B -26.66B -2.13B -2.08B -91.78B 89.73M 78.42M 72.49M 66.97M 126M 8.62B 128M 864M 339M 4.22B 337M 330M 14.53B
Net Debt -566M -494M -457M -422M -795M -54.32B -809M -5.45B -2.14B -26.6B -2.12B -2.08B -91.58B -983M -859M -794M -734M -1.38B -94.43B -1.41B -9.47B -3.72B -46.24B -3.69B -3.61B -159B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-07-15 US$109.14 -0.88% 62,601
26-07-14 US$110.11 +0.89% 1,848,330
26-07-13 US$109.14 -5.60% 2,825,240
26-07-10 US$115.61 -2.24% 2,931,618
26-07-09 US$118.26 +1.48% 3,167,091
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
110.11USD
Average target price
196.33USD
Spread / Average Target
+78.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock